

Table 1

<i>In-vivo</i> optical imaging methods to detect OPMD	Basic principle	Advantages	Inconvenient	Interesting studies on methods to detect OPMD
Autofluorescence imaging (AFI)	<p>Visualization of the autofluorescence from endogenous fluorophores (NADH and FAD)</p> <p>Metabolic and morphologic changes related to carcinologic process lead to autofluorescence loss.</p> <p>Altered/dysplastic mucosa appears darker compared with the healthy surroundings.</p>	<p>Practical</p> <p>Cost-effective</p> <p>Non-invasive</p>	<p>Low specificity:</p> <ul style="list-style-type: none"> - False positives: tissues with rich micro vascularity (granulation tissue, inflammation, and edema) - False negatives: regions with hyperkeratosis (Leukoplakia+++) or overgrowth of bacteria (producing extra fluorophores) 	<p>[5]</p> <p>[72]</p> <p>[73]</p>
Targeted Fluorescence imaging (TFI)	Visualization of a fluorescence probe specifically targeting the neoplastic tissues	The targeted immune -fluorescence imaging: targeting an over-expressed protein by approved antibodies	Intra-tumor phenotype heterogeneity decreases its sensitivity	[5]
Narrow band imaging (NBI)	Visualization of the neoangiogenic patterns of tissues using an illumination light within the absorption spectrum of hemoglobin	<p>The abnormal intra epithelial capillary loops (ICPL) patterns can be used to differentiate neoplastic from normal tissues</p> <p>The NBI endoscopic system is widely available</p>	Characterization of IPCL patterns is subjective and false positive results are frequent (level of keratinization, lymphoid tissue, previous radiation or surgery, inflammation and vascular lesions)	<p>[5]</p> <p>[76]</p> <p>[77]</p>
High resolution microendoscopy (HRME)	Visualization of an emitted light by superficially applied fluorophores using a flexible fiber-optic probe placed in direct contact with the suspicious tissue	<p>Cost effective</p> <p>Noninvasive</p> <p>High resolution</p> <p>High sensitivity and specificity</p> <p>Simple and portable device</p> <p>Requires minimal training</p> <p>High inter-rater reliability</p>	<p>Not commercially available</p> <p>The proflavine (the most commonly used contrast agent) is not approved for <i>in-vivo</i> clinical use</p> <p>Limited field-of-view</p>	<p>[5]</p> <p>[78]</p>
Raman Spectroscopy (RS)	Visualization of the 'molecular fingerprint' (i.e. variations of chemical components) of a tissue using vibrational spectroscopic technique	<p>Water absorption does not disturb the measurement</p> <p>High signal-to-noise ratio</p> <p>Fewer sample volumes are required for analysis.</p>	<p>Analyzes are difficult</p> <p>No commercially available</p> <p>Too large for routine clinical use</p> <p>Time consuming</p>	<p>[5]</p> <p>[79]</p> <p>[80]</p> <p>[81]</p> <p>[82]</p>

Table 2

Cell line	Dysplasia features	References
D9	Mild or Moderate dysplasia of ventral tongue	[48]
D20	Moderate dysplasia of lateral tongue	[48]
D34	Moderate dysplasia of posterolateral tongue	[48]
D38	Mild dysplasia of lateral tongue	[48]
DOK (dysplastic oral keratinocyte)	Epithelial dysplasia from the dorsal tongue of a 57-year-old heavy smoker	[89]
POE9n	Severely dysplastic oral epithelial lesion of a 65-year-old male possessing a homozygous deletion at the p16INK4A/p14ARF locus, lacking p53 expression, and exhibiting an extended but finite replicative life span	[90]
MSK Leuk1	Spontaneously derived from an oral leukoplakia lesion	[91]
Leuk1	Dysplastic leukoplakia adjacent an early invasive OSCC (T1N0M0) involving the tongue of a 47-year-old female	[92]
Leuk2	Dysplastic leukoplakia in a 72-year-old female with a history of recurrent new disease	[92]
LDOK	Severe dysplasia on the lingual alveolus, carrying a p53 gene mutation (G-T at codon 248) and does not express p16	[93]
CDOK	Mild dysplasia at the commissure	[93]
LTDOK	Mild dysplasia on the lateral tongue	[93]
SPDOK	Moderate dysplasia on the soft palate	[93]
VU-pre-SCC M3	Glottic laryngeal tumor with dysplasia in the mucosal resection margin	[47] & [94]